 Paul Maroni
Concepts (351)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 39 | 2024 | 972 | 3.730 |
Why?
| | Prostatectomy | 8 | 2019 | 93 | 1.440 |
Why?
| | Testicular Neoplasms | 7 | 2023 | 108 | 1.070 |
Why?
| | Urology | 3 | 2020 | 60 | 0.810 |
Why?
| | Embolism | 1 | 2021 | 49 | 0.660 |
Why?
| | Urethra | 1 | 2021 | 55 | 0.660 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 3 | 2023 | 76 | 0.660 |
Why?
| | Androgen Antagonists | 4 | 2024 | 91 | 0.650 |
Why?
| | Laser Therapy | 1 | 2021 | 146 | 0.590 |
Why?
| | Kidney Medulla | 2 | 2005 | 28 | 0.440 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1062 | 0.440 |
Why?
| | Early Detection of Cancer | 5 | 2023 | 501 | 0.380 |
Why?
| | Neoadjuvant Therapy | 2 | 2021 | 474 | 0.340 |
Why?
| | Urination Disorders | 1 | 2011 | 15 | 0.340 |
Why?
| | Prostate-Specific Antigen | 8 | 2020 | 162 | 0.340 |
Why?
| | Male | 56 | 2024 | 73014 | 0.320 |
Why?
| | Prostate | 7 | 2023 | 159 | 0.320 |
Why?
| | Oxalates | 2 | 2008 | 7 | 0.300 |
Why?
| | Neoplasm Grading | 5 | 2021 | 313 | 0.270 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2014 | 1754 | 0.260 |
Why?
| | Adenocarcinoma | 3 | 2022 | 927 | 0.250 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2018 | 222 | 0.250 |
Why?
| | Humans | 59 | 2024 | 145625 | 0.240 |
Why?
| | Neoplasm Staging | 7 | 2021 | 1486 | 0.230 |
Why?
| | Kidney Tubules, Collecting | 1 | 2005 | 25 | 0.220 |
Why?
| | Oxalic Acid | 1 | 2004 | 3 | 0.220 |
Why?
| | Brachytherapy | 2 | 2016 | 132 | 0.210 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2021 | 257 | 0.200 |
Why?
| | Clinical Competence | 1 | 2012 | 1261 | 0.200 |
Why?
| | Androgens | 4 | 2024 | 179 | 0.190 |
Why?
| | Paraganglioma | 1 | 2022 | 65 | 0.170 |
Why?
| | Cell Hypoxia | 2 | 2015 | 247 | 0.170 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2022 | 99 | 0.170 |
Why?
| | Prolactin | 3 | 1997 | 88 | 0.160 |
Why?
| | Cation Transport Proteins | 1 | 2022 | 120 | 0.160 |
Why?
| | Adaptor Proteins, Vesicular Transport | 2 | 1997 | 46 | 0.160 |
Why?
| | Surveys and Questionnaires | 3 | 2017 | 6050 | 0.160 |
Why?
| | Orchiectomy | 3 | 2016 | 72 | 0.160 |
Why?
| | Magnetic Resonance Imaging, Interventional | 1 | 2020 | 30 | 0.160 |
Why?
| | Aged | 21 | 2021 | 26251 | 0.150 |
Why?
| | Risk Assessment | 4 | 2020 | 3678 | 0.150 |
Why?
| | Middle Aged | 20 | 2021 | 36359 | 0.150 |
Why?
| | Salvage Therapy | 2 | 2018 | 163 | 0.150 |
Why?
| | Proanthocyanidins | 1 | 2019 | 6 | 0.150 |
Why?
| | Biflavonoids | 1 | 2019 | 6 | 0.150 |
Why?
| | Stromal Cells | 1 | 2019 | 123 | 0.140 |
Why?
| | Grape Seed Extract | 1 | 2019 | 29 | 0.140 |
Why?
| | Anthocyanins | 1 | 2019 | 28 | 0.140 |
Why?
| | Catechin | 1 | 2019 | 23 | 0.140 |
Why?
| | Euterpe | 1 | 2018 | 4 | 0.140 |
Why?
| | Hospitals | 2 | 2023 | 730 | 0.140 |
Why?
| | Nomograms | 1 | 2019 | 59 | 0.140 |
Why?
| | Digital Rectal Examination | 1 | 2018 | 10 | 0.140 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2018 | 33 | 0.130 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2019 | 178 | 0.130 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 1997 | 427 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 1997 | 126 | 0.130 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2018 | 1156 | 0.130 |
Why?
| | Biopsy, Needle | 2 | 2016 | 182 | 0.130 |
Why?
| | Urinary Tract Infections | 1 | 2019 | 207 | 0.130 |
Why?
| | Proton Therapy | 1 | 2017 | 16 | 0.130 |
Why?
| | Seminoma | 1 | 2017 | 20 | 0.120 |
Why?
| | Surgical Wound Infection | 2 | 2019 | 331 | 0.120 |
Why?
| | Plant Extracts | 1 | 2018 | 191 | 0.120 |
Why?
| | Sertoli-Leydig Cell Tumor | 1 | 2016 | 8 | 0.120 |
Why?
| | Neoplasm Metastasis | 5 | 2019 | 693 | 0.120 |
Why?
| | Radiology | 1 | 2019 | 175 | 0.120 |
Why?
| | Spectrum Analysis | 1 | 2016 | 85 | 0.120 |
Why?
| | Liver | 4 | 1997 | 1859 | 0.120 |
Why?
| | Sex Cord-Gonadal Stromal Tumors | 1 | 2015 | 5 | 0.120 |
Why?
| | Medical Oncology | 1 | 2019 | 344 | 0.110 |
Why?
| | Radiotherapy, Conformal | 1 | 2015 | 75 | 0.110 |
Why?
| | Prognosis | 7 | 2019 | 4331 | 0.110 |
Why?
| | Proto-Oncogene Proteins | 2 | 1997 | 615 | 0.110 |
Why?
| | Risk | 2 | 2015 | 917 | 0.110 |
Why?
| | Lymphatic Metastasis | 3 | 2014 | 335 | 0.110 |
Why?
| | Neoplastic Stem Cells | 1 | 2019 | 402 | 0.110 |
Why?
| | HSP70 Heat-Shock Proteins | 2 | 2008 | 76 | 0.110 |
Why?
| | Biopsy | 4 | 2023 | 1073 | 0.100 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2015 | 165 | 0.100 |
Why?
| | Leydig Cell Tumor | 1 | 2014 | 8 | 0.100 |
Why?
| | Genomics | 1 | 2019 | 851 | 0.100 |
Why?
| | Cause of Death | 1 | 2016 | 455 | 0.100 |
Why?
| | Priapism | 1 | 2013 | 9 | 0.100 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 2013 | 19 | 0.100 |
Why?
| | Hypertension | 1 | 2022 | 1270 | 0.100 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2013 | 34 | 0.100 |
Why?
| | Optics and Photonics | 1 | 2014 | 38 | 0.100 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2013 | 18 | 0.100 |
Why?
| | Spectrometry, Fluorescence | 1 | 2014 | 165 | 0.100 |
Why?
| | Proline | 1 | 2013 | 79 | 0.100 |
Why?
| | Triglycerides | 1 | 2015 | 527 | 0.090 |
Why?
| | Extracellular Vesicles | 1 | 2015 | 175 | 0.090 |
Why?
| | Matrix Metalloproteinase 9 | 2 | 2010 | 128 | 0.090 |
Why?
| | Treatment Outcome | 7 | 2018 | 11744 | 0.090 |
Why?
| | Neoplasm Invasiveness | 4 | 2016 | 503 | 0.090 |
Why?
| | Drug Interactions | 1 | 2013 | 403 | 0.090 |
Why?
| | Telephone | 1 | 2013 | 175 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2024 | 2218 | 0.090 |
Why?
| | Cell Line | 3 | 2008 | 2809 | 0.080 |
Why?
| | Urothelium | 1 | 2011 | 33 | 0.080 |
Why?
| | Signal Transduction | 4 | 2004 | 5234 | 0.080 |
Why?
| | Survival Rate | 4 | 2017 | 2078 | 0.080 |
Why?
| | Lymph Nodes | 1 | 2014 | 511 | 0.080 |
Why?
| | Prostatic Hyperplasia | 1 | 2011 | 40 | 0.080 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 4 | 2008 | 169 | 0.080 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2011 | 81 | 0.080 |
Why?
| | Spinal Fractures | 1 | 2011 | 81 | 0.080 |
Why?
| | Attitude of Health Personnel | 1 | 2019 | 1212 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 2010 | 54 | 0.080 |
Why?
| | Epithelial Cells | 2 | 2008 | 1118 | 0.080 |
Why?
| | Combined Modality Therapy | 2 | 2016 | 1269 | 0.080 |
Why?
| | Carcinogenesis | 2 | 2022 | 226 | 0.080 |
Why?
| | Oxygen | 1 | 2015 | 996 | 0.080 |
Why?
| | Survival Analysis | 2 | 2016 | 1372 | 0.080 |
Why?
| | Glucose | 1 | 2015 | 1051 | 0.080 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 3 | 2008 | 133 | 0.080 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 2 | 2009 | 262 | 0.080 |
Why?
| | Counseling | 1 | 2013 | 403 | 0.080 |
Why?
| | Aged, 80 and over | 6 | 2020 | 8351 | 0.080 |
Why?
| | Carcinoma | 1 | 2011 | 225 | 0.070 |
Why?
| | Decision Making | 1 | 2017 | 987 | 0.070 |
Why?
| | Lymph Node Excision | 2 | 2014 | 173 | 0.070 |
Why?
| | Survivors | 1 | 2013 | 521 | 0.070 |
Why?
| | Lymphatic Diseases | 1 | 2009 | 21 | 0.070 |
Why?
| | Postoperative Complications | 2 | 2019 | 2962 | 0.070 |
Why?
| | Cystitis | 1 | 2009 | 24 | 0.070 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2008 | 34 | 0.070 |
Why?
| | Age Factors | 4 | 2017 | 3321 | 0.070 |
Why?
| | Logistic Models | 3 | 2019 | 2112 | 0.070 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2008 | 33 | 0.070 |
Why?
| | Patient Education as Topic | 1 | 2013 | 769 | 0.070 |
Why?
| | Patient Selection | 2 | 2018 | 720 | 0.070 |
Why?
| | Proportional Hazards Models | 3 | 2016 | 1318 | 0.060 |
Why?
| | Databases, Factual | 3 | 2019 | 1481 | 0.060 |
Why?
| | Cell Line, Tumor | 5 | 2015 | 3538 | 0.060 |
Why?
| | Kidney Tubules, Proximal | 1 | 2008 | 127 | 0.060 |
Why?
| | Image-Guided Biopsy | 2 | 2020 | 41 | 0.060 |
Why?
| | Societies, Medical | 1 | 2011 | 901 | 0.060 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 2 | 1997 | 165 | 0.060 |
Why?
| | Diagnostic Imaging | 2 | 2022 | 340 | 0.060 |
Why?
| | Time Factors | 4 | 2014 | 7079 | 0.060 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 299 | 0.060 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2008 | 429 | 0.060 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2008 | 196 | 0.060 |
Why?
| | Radiotherapy Dosage | 2 | 2018 | 289 | 0.060 |
Why?
| | Adult | 12 | 2020 | 40821 | 0.060 |
Why?
| | Reactive Oxygen Species | 2 | 2009 | 610 | 0.060 |
Why?
| | Animals | 11 | 2022 | 38030 | 0.060 |
Why?
| | Follow-Up Studies | 4 | 2016 | 5397 | 0.060 |
Why?
| | Oxidative Stress | 2 | 2010 | 1367 | 0.060 |
Why?
| | Isoflavones | 1 | 2005 | 25 | 0.060 |
Why?
| | Ear, Inner | 1 | 2005 | 43 | 0.060 |
Why?
| | Young Adult | 6 | 2020 | 14240 | 0.060 |
Why?
| | Support Vector Machine | 2 | 2016 | 33 | 0.060 |
Why?
| | Mitotic Index | 2 | 2015 | 24 | 0.050 |
Why?
| | History, 21st Century | 1 | 2006 | 224 | 0.050 |
Why?
| | Body Fluids | 1 | 2005 | 70 | 0.050 |
Why?
| | Mice | 4 | 2022 | 18266 | 0.050 |
Why?
| | Cell Count | 1 | 2005 | 315 | 0.050 |
Why?
| | Urinary Incontinence | 1 | 2005 | 65 | 0.050 |
Why?
| | MAP Kinase Signaling System | 2 | 2008 | 306 | 0.050 |
Why?
| | Growth | 1 | 2004 | 48 | 0.050 |
Why?
| | Kidney Neoplasms | 1 | 2009 | 417 | 0.050 |
Why?
| | Informed Consent | 1 | 2006 | 194 | 0.050 |
Why?
| | Disease Progression | 2 | 2018 | 2857 | 0.050 |
Why?
| | Propensity Score | 2 | 2016 | 370 | 0.050 |
Why?
| | Cell Proliferation | 3 | 2019 | 2497 | 0.050 |
Why?
| | Mass Screening | 2 | 2015 | 1300 | 0.050 |
Why?
| | Receptors, Nicotinic | 1 | 2005 | 327 | 0.050 |
Why?
| | Protein-Tyrosine Kinases | 2 | 1997 | 429 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1531 | 0.050 |
Why?
| | United States | 5 | 2019 | 16041 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 2 | 2016 | 959 | 0.050 |
Why?
| | Transcriptional Regulator ERG | 1 | 2022 | 14 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 2218 | 0.040 |
Why?
| | Urinary Bladder | 1 | 2004 | 194 | 0.040 |
Why?
| | Sensitivity and Specificity | 3 | 2016 | 1992 | 0.040 |
Why?
| | Rats, Wistar | 3 | 1997 | 449 | 0.040 |
Why?
| | Rats | 6 | 2005 | 5574 | 0.040 |
Why?
| | Intestines | 1 | 2004 | 351 | 0.040 |
Why?
| | Cell Survival | 2 | 2019 | 1102 | 0.040 |
Why?
| | Serine Endopeptidases | 1 | 2022 | 129 | 0.040 |
Why?
| | Src Homology 2 Domain-Containing, Transforming Protein 1 | 2 | 1997 | 10 | 0.040 |
Why?
| | Shc Signaling Adaptor Proteins | 2 | 1997 | 10 | 0.040 |
Why?
| | Testosterone | 2 | 2015 | 419 | 0.040 |
Why?
| | Hyperthermia, Induced | 1 | 2001 | 119 | 0.040 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2001 | 266 | 0.040 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2022 | 212 | 0.040 |
Why?
| | Biomarkers, Tumor | 2 | 2020 | 1334 | 0.040 |
Why?
| | Fever | 1 | 2001 | 320 | 0.040 |
Why?
| | Adolescent | 5 | 2022 | 22451 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinases | 2 | 2001 | 288 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2022 | 314 | 0.040 |
Why?
| | Cerebellum | 1 | 2001 | 225 | 0.040 |
Why?
| | Reperfusion | 2 | 1996 | 53 | 0.040 |
Why?
| | Jagged-1 Protein | 1 | 2019 | 22 | 0.040 |
Why?
| | Feeding Behavior | 1 | 2005 | 691 | 0.040 |
Why?
| | Geography | 1 | 2019 | 186 | 0.040 |
Why?
| | Inflammation | 1 | 2010 | 2915 | 0.040 |
Why?
| | Receptor, Notch1 | 1 | 2019 | 62 | 0.040 |
Why?
| | Retrospective Studies | 4 | 2023 | 17291 | 0.040 |
Why?
| | Zinc | 1 | 2022 | 310 | 0.030 |
Why?
| | Fruit and Vegetable Juices | 1 | 2018 | 23 | 0.030 |
Why?
| | Tissue Kallikreins | 1 | 2018 | 2 | 0.030 |
Why?
| | Enzyme Activation | 4 | 2008 | 758 | 0.030 |
Why?
| | Radiometry | 1 | 2018 | 56 | 0.030 |
Why?
| | Stress, Physiological | 1 | 2001 | 449 | 0.030 |
Why?
| | Kallikreins | 1 | 2018 | 25 | 0.030 |
Why?
| | Spheroids, Cellular | 1 | 2019 | 81 | 0.030 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2019 | 122 | 0.030 |
Why?
| | Enzyme Induction | 1 | 1997 | 87 | 0.030 |
Why?
| | Janus Kinase 2 | 1 | 1997 | 31 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2005 | 4112 | 0.030 |
Why?
| | Quality of Life | 2 | 2013 | 3187 | 0.030 |
Why?
| | MAP Kinase Kinase 1 | 1 | 1997 | 70 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2022 | 728 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2019 | 878 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 143 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2019 | 538 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 55 | 0.030 |
Why?
| | Phosphorylation | 4 | 2008 | 1717 | 0.030 |
Why?
| | Phenotype | 3 | 2010 | 3186 | 0.030 |
Why?
| | Protein Kinase C | 2 | 1994 | 250 | 0.030 |
Why?
| | Ultrasonography | 1 | 2020 | 788 | 0.030 |
Why?
| | Prospective Studies | 2 | 2020 | 8087 | 0.030 |
Why?
| | Feminization | 1 | 2015 | 6 | 0.030 |
Why?
| | Epoxy Compounds | 1 | 2015 | 31 | 0.030 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2015 | 49 | 0.030 |
Why?
| | Altitude | 1 | 2019 | 469 | 0.030 |
Why?
| | Heterografts | 1 | 2015 | 143 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2019 | 578 | 0.030 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 1995 | 127 | 0.030 |
Why?
| | Ischemia | 2 | 1996 | 421 | 0.030 |
Why?
| | Proteins | 2 | 1997 | 1021 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 777 | 0.030 |
Why?
| | Cell Movement | 1 | 2019 | 950 | 0.030 |
Why?
| | Female | 7 | 2021 | 79080 | 0.030 |
Why?
| | Colorado | 2 | 2015 | 4588 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2010 | 1709 | 0.030 |
Why?
| | Least-Squares Analysis | 1 | 2014 | 73 | 0.030 |
Why?
| | Mice, Nude | 1 | 2015 | 665 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 342 | 0.020 |
Why?
| | Needles | 1 | 2014 | 61 | 0.020 |
Why?
| | Risk Factors | 2 | 2019 | 10840 | 0.020 |
Why?
| | Radiotherapy | 1 | 2014 | 209 | 0.020 |
Why?
| | SEER Program | 1 | 2014 | 233 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 1995 | 415 | 0.020 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2013 | 93 | 0.020 |
Why?
| | Estrogens | 1 | 2015 | 364 | 0.020 |
Why?
| | Aging | 3 | 2010 | 1983 | 0.020 |
Why?
| | Equipment Design | 1 | 2014 | 519 | 0.020 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 1995 | 411 | 0.020 |
Why?
| | Child | 3 | 2022 | 22638 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2015 | 533 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2015 | 1075 | 0.020 |
Why?
| | Population Surveillance | 1 | 2014 | 477 | 0.020 |
Why?
| | Reoperation | 1 | 2014 | 633 | 0.020 |
Why?
| | Cell Separation | 1 | 2011 | 300 | 0.020 |
Why?
| | Life Style | 1 | 2013 | 495 | 0.020 |
Why?
| | Apoptosis | 1 | 2019 | 2436 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2011 | 333 | 0.020 |
Why?
| | Atrophy | 1 | 2010 | 199 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2011 | 403 | 0.020 |
Why?
| | Anxiety | 1 | 2017 | 1118 | 0.020 |
Why?
| | DNA Primers | 1 | 2010 | 487 | 0.020 |
Why?
| | Nephrolithiasis | 1 | 2009 | 10 | 0.020 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 2 | 2001 | 153 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 6045 | 0.020 |
Why?
| | Prostatitis | 1 | 2009 | 17 | 0.020 |
Why?
| | Metaplasia | 1 | 2009 | 54 | 0.020 |
Why?
| | Tumor Stem Cell Assay | 1 | 2008 | 33 | 0.020 |
Why?
| | Imaging, Three-Dimensional | 1 | 2012 | 578 | 0.020 |
Why?
| | Social Support | 1 | 2013 | 644 | 0.020 |
Why?
| | Incidence | 1 | 2015 | 2910 | 0.020 |
Why?
| | Anoikis | 1 | 2008 | 30 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2013 | 1323 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2013 | 1125 | 0.020 |
Why?
| | NADPH Oxidases | 1 | 2009 | 122 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 973 | 0.020 |
Why?
| | Immunoblotting | 2 | 2001 | 294 | 0.020 |
Why?
| | Genes, Immediate-Early | 1 | 2008 | 25 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2008 | 51 | 0.020 |
Why?
| | Tyrosine | 2 | 2001 | 217 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1176 | 0.020 |
Why?
| | Receptors, Androgen | 1 | 2009 | 149 | 0.020 |
Why?
| | Gonadal Steroid Hormones | 1 | 2009 | 143 | 0.020 |
Why?
| | Adaptation, Psychological | 1 | 2013 | 718 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1370 | 0.020 |
Why?
| | DNA, Mitochondrial | 1 | 2009 | 212 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 3917 | 0.020 |
Why?
| | Pilot Projects | 1 | 2013 | 1878 | 0.020 |
Why?
| | Glutathione | 1 | 2009 | 369 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2008 | 2783 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2119 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2008 | 157 | 0.010 |
Why?
| | RNA, Small Interfering | 1 | 2008 | 630 | 0.010 |
Why?
| | Models, Animal | 1 | 2008 | 386 | 0.010 |
Why?
| | Phosphotyrosine | 2 | 1996 | 38 | 0.010 |
Why?
| | Chinchilla | 1 | 2005 | 35 | 0.010 |
Why?
| | Equol | 1 | 2005 | 5 | 0.010 |
Why?
| | Guinea Pigs | 1 | 2005 | 159 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2015 | 1411 | 0.010 |
Why?
| | Antioxidants | 1 | 2009 | 544 | 0.010 |
Why?
| | Swine | 1 | 2008 | 821 | 0.010 |
Why?
| | Bladder Exstrophy | 1 | 2004 | 18 | 0.010 |
Why?
| | Acid-Base Equilibrium | 1 | 2004 | 23 | 0.010 |
Why?
| | Meat | 1 | 2005 | 62 | 0.010 |
Why?
| | Bicarbonates | 1 | 2004 | 44 | 0.010 |
Why?
| | Stress, Psychological | 1 | 2013 | 1169 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1500 | 0.010 |
Why?
| | Biomarkers | 1 | 2015 | 4329 | 0.010 |
Why?
| | Meningomyelocele | 1 | 2004 | 63 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2015 | 6449 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2766 | 0.010 |
Why?
| | Body Height | 1 | 2004 | 202 | 0.010 |
Why?
| | Hypoxia | 1 | 2010 | 1209 | 0.010 |
Why?
| | Referral and Consultation | 1 | 2009 | 878 | 0.010 |
Why?
| | Receptor, IGF Type 1 | 1 | 2001 | 64 | 0.010 |
Why?
| | Infant | 1 | 2015 | 10093 | 0.010 |
Why?
| | Bone Density | 1 | 2004 | 492 | 0.010 |
Why?
| | Child, Preschool | 1 | 2015 | 11888 | 0.010 |
Why?
| | Animals, Newborn | 1 | 2001 | 887 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2591 | 0.010 |
Why?
| | ErbB Receptors | 1 | 2001 | 636 | 0.010 |
Why?
| | Mutation | 1 | 2009 | 4082 | 0.010 |
Why?
| | Neoplasms | 1 | 2013 | 2944 | 0.010 |
Why?
| | GRB2 Adaptor Protein | 1 | 1996 | 12 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 1996 | 46 | 0.010 |
Why?
| | Sialoglycoproteins | 1 | 1996 | 157 | 0.010 |
Why?
| | Neurons | 1 | 2005 | 1663 | 0.010 |
Why?
| | Receptors, Interleukin-1 | 1 | 1996 | 211 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2001 | 2533 | 0.010 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 1996 | 253 | 0.010 |
Why?
| | Lymphocyte Count | 1 | 1995 | 166 | 0.010 |
Why?
| | Phosphotransferases | 1 | 1994 | 26 | 0.010 |
Why?
| | Precipitin Tests | 1 | 1994 | 90 | 0.010 |
Why?
| | Densitometry | 1 | 1994 | 36 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 1995 | 280 | 0.010 |
Why?
| | Injections, Intraperitoneal | 1 | 1994 | 115 | 0.010 |
Why?
| | Ornithine Decarboxylase | 1 | 1994 | 12 | 0.010 |
Why?
| | Genes, myc | 1 | 1994 | 45 | 0.010 |
Why?
| | Molecular Weight | 1 | 1994 | 295 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1994 | 326 | 0.010 |
Why?
| | Cytosol | 1 | 1994 | 215 | 0.010 |
Why?
| | Substrate Specificity | 1 | 1994 | 387 | 0.010 |
Why?
| | Kinetics | 1 | 1996 | 1553 | 0.010 |
Why?
| | Interleukin-1 | 1 | 1996 | 960 | 0.010 |
Why?
| | Gene Expression | 1 | 1994 | 1461 | 0.000 |
Why?
| | Antibodies, Monoclonal | 1 | 1994 | 1511 | 0.000 |
Why?
| | T-Lymphocytes | 1 | 1995 | 2007 | 0.000 |
Why?
|
|
Maroni's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|